BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
Number Citing Articles
1 Hwang YH, Kim DG, Li W, Yang HJ, Yim NH, Ma JY. Anti-inflammatory effects of Forsythia suspensa in dextran sulfate sodium-induced colitis. J Ethnopharmacol. 2017;206:73-77. [PMID: 28502906 DOI: 10.1016/j.jep.2017.05.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
2 Schultz M, Burton J. Escherichia coli Nissle 1917. The Microbiota in Gastrointestinal Pathophysiology. Elsevier; 2017. pp. 59-69. [DOI: 10.1016/b978-0-12-804024-9.00005-7] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 van Gennep S, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflamm Bowel Dis 2017;24:67-77. [PMID: 29272488 DOI: 10.1093/ibd/izx025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Kaplan GG, Jess T. The Changing Landscape of Inflammatory Bowel Disease: East Meets West. Gastroenterology. 2016;150:24-26. [PMID: 26592321 DOI: 10.1053/j.gastro.2015.11.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
5 Zhang L, Wu YB, Dai YK, Liu Q, Ren YJ, Xu SJ, Pan HG, Chen WJ, Li RL, Hu L. Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. PLoS One 2021;16:e0257599. [PMID: 34543327 DOI: 10.1371/journal.pone.0257599] [Reference Citation Analysis]
6 Fukuda T, Naganuma M, Sugimoto S, Nanki K, Mizuno S, Mutaguchi M, Nakazato Y, Inoue N, Ogata H, Iwao Y, Kanai T. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry. PLoS One 2017;12:e0187737. [PMID: 29108025 DOI: 10.1371/journal.pone.0187737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
7 Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis. Drug Saf 2019;42:617-32. [DOI: 10.1007/s40264-018-00783-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci 2019;56:307-20. [PMID: 31088326 DOI: 10.1080/10408363.2019.1619159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
9 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
11 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
12 You W, Xu Z, Di A, Liu P, Pang C, Wang J, Li X, Wang Y, Yu B, Liu X, Zhao G. Mechanism by Which Tong Xie Yao Fang Heals the Intestinal Mucosa of Rats with Ulcerative Colitis through the Hippo Pathway. Evid Based Complement Alternat Med 2021;2021:5533914. [PMID: 34504536 DOI: 10.1155/2021/5533914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology 2019;157:320-48. [DOI: 10.1053/j.gastro.2019.03.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
14 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
15 Chen S, Zhang CL, Shen HQ, Zhou XF, Li JH, Yu JL, An Q, Fu BD, Yi PF. Sesamin protects against DSS-induced colitis in mice by inhibiting NF-κB and MAPK signaling pathways. Food Funct 2021;12:1688-94. [PMID: 33496702 DOI: 10.1039/d0fo00950d] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
17 Pandey M, Choudhury H, D/O Segar Singh SK, Chetty Annan N, Bhattamisra SK, Gorain B, Mohd Amin MCI. Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. Molecules 2021;26:2704. [PMID: 34062995 DOI: 10.3390/molecules26092704] [Reference Citation Analysis]
18 Steenholdt C. Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive. Clin Gastroenterol Hepatol 2018;16:597-8. [PMID: 29555230 DOI: 10.1016/j.cgh.2017.11.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN. Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol 2018;113:1206-16. [PMID: 29925912 DOI: 10.1038/s41395-018-0108-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
21 Meijer B, Mulder CJ, van Bodegraven AA, de Boer NKH. How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther 2016; 7(4): 524-530 [PMID: 27867685 DOI: 10.4292/wjgpt.v7.i4.524] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Baer PA, Aumais G, Ewara EM, Khraishi M, Marrache AM, Panaccione R, Wade JP, Marshall JK. Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. Patient Prefer Adherence 2018;12:1805-14. [PMID: 30271124 DOI: 10.2147/PPA.S171363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
24 Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol 2018;32-33:43-7. [PMID: 30060938 DOI: 10.1016/j.bpg.2018.05.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
25 Hu J, Zhao G, Zhang L, Qiao C, Di A, Gao H, Xu H. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med 2016;12:2983-9. [PMID: 27882104 DOI: 10.3892/etm.2016.3724] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
26 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
28 Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis 2016;22:1881-6. [PMID: 27416045 DOI: 10.1097/MIB.0000000000000860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2017;46:292-302. [PMID: 28568974 DOI: 10.1111/apt.14164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
30 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e35-63. [PMID: 31294379 DOI: 10.1093/jcag/gwz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
31 Orlandini B, Dragoni G, Variola A, Massella A, Bagnoli S, Campi R, Rogai F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. J Dig Dis 2018;19:468-74. [PMID: 30039533 DOI: 10.1111/1751-2980.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Huang JY, Nong H, Pei X, Huang X, Tan ZR, Qin MB, Li H, Zhang YQ. Mechanism underlying effect of Sijunzi decoction on intestinal mucosal barrier of mice with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(27): 4326-4334 [DOI: 10.11569/wcjd.v23.i27.4326] [Reference Citation Analysis]
33 Li K, Dong J, Ge D, Li M, Ye H, Wang X, Wu Y. The Effects of Sishen Wan on T Cell Responses in Mice Models of Ulcerative Colitis Induced by Dextran Sodium Sulfate. Evid Based Complement Alternat Med 2021;2021:9957709. [PMID: 34956391 DOI: 10.1155/2021/9957709] [Reference Citation Analysis]
34 Harzallah I, Rigaill J, Williet N, Paul S, Roblin X. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol 2017;10:89-100. [PMID: 28286562 DOI: 10.1177/1756283X16676194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Lin JC, Wu JQ, Wang F, Tang FY, Sun J, Xu B, Jiang M, Chu Y, Chen D, Li X, Su S, Zhang Y, Wu N, Yang S, Wu K, Liang J. QingBai decoction regulates intestinal permeability of dextran sulphate sodium-induced colitis through the modulation of notch and NF-κB signalling. Cell Prolif 2019;52:e12547. [PMID: 30657238 DOI: 10.1111/cpr.12547] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
36 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
38 Wilson A, Jansen LE, Rose RV, Gregor JC, Ponich T, Chande N, Khanna R, Yan B, Jairath V, Khanna N, Sey M, Beaton M, McIntosh K, Teft WA, Kim RB. HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:615-620. [PMID: 29270995 DOI: 10.1111/apt.14483] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
39 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
40 Hishinuma K, Moroi R, Okamoto D, Shimoyama Y, Kuroha M, Shiga H, Kakuta Y, Kinouchi Y, Masamune A. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci. Inflamm Intest Dis 2021;6:154-64. [PMID: 34722645 DOI: 10.1159/000518371] [Reference Citation Analysis]
41 Zhang Y, Wang J, Hou D, Yan S, Dang S. To assess the effective and safety of berberine hydrochloride in ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23482. [PMID: 33285751 DOI: 10.1097/MD.0000000000023482] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus. Inflammatory Bowel Diseases 2019;25:1-13. [DOI: 10.1093/ibd/izy247] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
43 Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2019;156:946-957.e18. [PMID: 30472236 DOI: 10.1053/j.gastro.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
44 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 189] [Article Influence: 32.0] [Reference Citation Analysis]
45 Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1760-1768.e1. [PMID: 31546056 DOI: 10.1016/j.cgh.2019.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
46 Chen W, Xiang L, Li L. Therapeutic Efficacy of the Combination Therapy of Corticosteroids and 5-Aminosalicylic Acid for Treatment of Pyoderma Gangrenosum with Ulcerative Colitis. Indian J Dermatol 2020;65:38-41. [PMID: 32029938 DOI: 10.4103/ijd.IJD_505_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones J, Lakatos PL, Sewitch M, El-Matary W, Melmed G, Nguyen G; QI consensus group; Promoting Access and Care through Centers of Excellence-PACE program). Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflamm Bowel Dis. 2019;25:403-409. [PMID: 30169582 DOI: 10.1093/ibd/izy259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
48 Jhaj G, Kopplin LJ. Ocular features of the HLA-B27-positive seronegative spondyloarthropathies. Current Opinion in Ophthalmology 2018;29:552-7. [DOI: 10.1097/icu.0000000000000525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Liu G, Jiang Q, Chen S, Fang J, Ren W, Yin J, Yao K, Yin Y. Melatonin alters amino acid metabolism and inflammatory responses in colitis mice. Amino Acids 2017;49:2065-71. [PMID: 28929336 DOI: 10.1007/s00726-017-2489-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
50 Lin YY, Zhao JM, Ji YJ, Ma Z, Zheng HD, Huang Y, Cui YH, Lu Y, Wu HG. Typical ulcerative colitis treated by herbs-partitioned moxibustion: A case report. World J Clin Cases 2020; 8(8): 1515-1524 [PMID: 32368545 DOI: 10.12998/wjcc.v8.i8.1515] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
52 He L, Wen S, Zhong Z, Weng S, Jiang Q, Mi H, Liu F. The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis. Front Pharmacol 2021;12:625543. [PMID: 34093178 DOI: 10.3389/fphar.2021.625543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol 2019;12:1756284819852231. [PMID: 31191713 DOI: 10.1177/1756284819852231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
54 Camilleri M, Katzka DA. Enhancing High Value Care in Gastroenterology Practice. Clin Gastroenterol Hepatol 2016;14:1376-84. [PMID: 27215366 DOI: 10.1016/j.cgh.2016.05.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Chao L, Li Z, Zhou J, Chen W, Li Y, Lv W, Guo A, Qu Q, Guo S. Shen-Ling-Bai-Zhu-San Improves Dextran Sodium Sulfate-Induced Colitis by Inhibiting Caspase-1/Caspase-11-Mediated Pyroptosis. Front Pharmacol 2020;11:814. [PMID: 32547403 DOI: 10.3389/fphar.2020.00814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
56 Lopes F, Matisz C, Reyes JL, Jijon H, Al-darmaki A, Kaplan GG, Mckay DM. Helminth Regulation of Immunity: A Three-pronged Approach to Treat Colitis. Inflammatory Bowel Diseases 2016;22:2499-512. [DOI: 10.1097/mib.0000000000000889] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
57 Li J, Kong D, Wang Q, Wu W, Tang Y, Bai T, Guo L, Wei L, Zhang Q, Yu Y, Qian Y, Zuo S, Liu G, Liu Q, Wu S, Zang Y, Zhu Q, Jia D, Wang Y, Yao W, Ji Y, Yin H, Nakamura M, Lazarus M, Breyer RM, Wang L, Yu Y. Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. EMBO Mol Med 2017;9:571-88. [PMID: 28341703 DOI: 10.15252/emmm.201606987] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
58 Yan BM, Sey MSL, Belletrutti P, Brahm G, Guizzetti L, Jairath V. Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis. Endosc Int Open 2021;9:E1116-22. [PMID: 34327283 DOI: 10.1055/a-1481-8032] [Reference Citation Analysis]
59 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Yang L, Meng X, Yu X, Kuang H. Simultaneous determination of anemoside B4, phellodendrine, berberine, palmatine, obakunone, esculin, esculetin in rat plasma by UPLC–ESI–MS/MS and its application to a comparative pharmacokinetic study in normal and ulcerative colitis rats. Journal of Pharmaceutical and Biomedical Analysis 2017;134:43-52. [DOI: 10.1016/j.jpba.2016.11.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
61 Deng Z, Cui C, Wang Y, Ni J, Zheng L, Wei H, Peng J. FSGHF3 and peptides, prepared from fish skin gelatin, exert a protective effect on DSS-induced colitis via the Nrf2 pathway. Food Funct 2020;11:414-23. [DOI: 10.1039/c9fo02165e] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
62 Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2106-12. [PMID: 29697791 DOI: 10.1093/ibd/izy076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
63 Jia J, Zheng K, Shen H, Yu J, Zhu P, Yan S, Xu Y, Zhu L, Lu Y, Gu P, Feng W. Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance. BMC Complement Med Ther 2020;20:291. [PMID: 32967687 DOI: 10.1186/s12906-020-03088-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
65 Elias ED, Targownik LE, Singh H, Bernstein CN. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflamm Bowel Dis 2020;26:150-7. [PMID: 31340002 DOI: 10.1093/ibd/izz148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
66 Lee-Kong S, Kiran RP. Ongoing challenges and controversies in ulcerative colitis surgery. Expert Rev Gastroenterol Hepatol. 2016;10:187-191. [PMID: 26577225 DOI: 10.1586/17474124.2016.1121811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
67 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Dai YC, Zheng L, Zhang YL, Chen X, Chen DL, Tang ZP. Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial. Medicine (Baltimore). 2017;96:e6651. [PMID: 28422869 DOI: 10.1097/md.0000000000006651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Targownik LE, Tennakoon A, Leung S, Lix LM, Nugent Z, Singh H, Bernstein CN. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis. Inflammatory Bowel Diseases 2017;23:409-20. [DOI: 10.1097/mib.0000000000001025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
70 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
71 Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Can J Gastroenterol Hepatol 2016;2016:2079582. [PMID: 27478817 DOI: 10.1155/2016/2079582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
72 Wang X, Yang YM, Yang T, An LY, Chen XZ, Qi YX, He HY, Fan HB, Sun DL. Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease. J Clin Pharm Ther 2021;46:599-609. [PMID: 33543814 DOI: 10.1111/jcpt.13368] [Reference Citation Analysis]
73 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
74 Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.Therap Adv Gastroenterol. 2016;9:330-338. [PMID: 27134663 DOI: 10.1177/1756283X16635081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
75 Richter JM, Arshi NK, Oster G. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. Can J Gastroenterol Hepatol 2016;2016:6928710. [PMID: 27446860 DOI: 10.1155/2016/6928710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Araújo DFS, Guerra GCB, Júnior RFA, Antunes de Araújo A, Antonino de Assis PO, Nunes de Medeiros A, Formiga de Sousa YR, Pintado MME, Gálvez J, Queiroga RCRDE. Goat whey ameliorates intestinal inflammation on acetic acid-induced colitis in rats. J Dairy Sci 2016;99:9383-94. [PMID: 27771081 DOI: 10.3168/jds.2016-10930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
77 Wei D, Xie L, Zhuang Z, Zhao N, Huang B, Tang Y, Yu S, Zhou Q, Wu Q. Gut Microbiota: A New Strategy to Study the Mechanism of Electroacupuncture and Moxibustion in Treating Ulcerative Colitis. Evid Based Complement Alternat Med. 2019;2019:9730176. [PMID: 31354859 DOI: 10.1155/2019/9730176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
78 Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. J Can Assoc Gastroenterol. 2018;1:129-134. [PMID: 31294354 DOI: 10.1093/jcag/gwy019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
79 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 311] [Article Influence: 60.3] [Reference Citation Analysis]
80 Dulai PS. Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival. Gastroenterology 2018;155:967-9. [PMID: 30201358 DOI: 10.1053/j.gastro.2018.09.007] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31388-4. [PMID: 33039584 DOI: 10.1016/j.cgh.2020.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
82 Zeng J, Lv L, Mei Z. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis: Budesonide foam for ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:558-66. [DOI: 10.1111/jgh.13604] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
83 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e1-e34. [PMID: 31294378 DOI: 10.1093/jcag/gwz019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
84 Bazarganipour S, Hausmann J, Oertel S, El-Hindi K, Brachtendorf S, Blumenstein I, Kubesch A, Sprinzl K, Birod K, Hahnefeld L, Trautmann S, Thomas D, Herrmann E, Geisslinger G, Schiffmann S, Grösch S. The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. J Clin Med 2019;8:E971. [PMID: 31277430 DOI: 10.3390/jcm8070971] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
85 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
86 Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Reference Citation Analysis]
87 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
88 Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. J Can Assoc Gastroenterol. 2018;1:141-154. [PMID: 31799497 DOI: 10.1093/jcag/gwy047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
89 Peyrin-biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of Crohn’s disease. Digestive and Liver Disease 2017;49:368-77. [DOI: 10.1016/j.dld.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
90 Heron V, Loftus EV Jr. Nonbiologic Immune Suppression in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:731-8. [PMID: 33121692 DOI: 10.1016/j.gtc.2020.07.003] [Reference Citation Analysis]
91 Yarlas A, Bayliss M, Cappelleri JC, Maher S, Bushmakin AG, Chen LA, Manuchehri A, Healey P. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review. Qual Life Res 2018;27:273-90. [DOI: 10.1007/s11136-017-1690-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
92 Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1028-35. [PMID: 30365009 DOI: 10.1093/ibd/izy323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
93 Cheifetz AS, Gianotti R, Luber R, Gibson PR. Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152:415-429.e15. [PMID: 27743873 DOI: 10.1053/j.gastro.2016.10.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 11.2] [Reference Citation Analysis]
94 Kandula M, Sunil Kumar K, Palanichamy S, Rampal A. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. International Immunopharmacology 2016;40:443-51. [DOI: 10.1016/j.intimp.2016.09.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
95 Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. BMC Gastroenterol 2021;21:77. [PMID: 33602145 DOI: 10.1186/s12876-021-01650-7] [Reference Citation Analysis]
96 Armuzzi A, DiBonaventura MD, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Quirk D, Salese L. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One 2020;15:e0227914. [PMID: 31945774 DOI: 10.1371/journal.pone.0227914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
97 Mitchell RA, Shuster C, Shahidi N, Galorport C, DeMarco ML, Rosenfeld G, Enns RA, Bressler B. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Can J Gastroenterol Hepatol 2016;2016:5203898. [PMID: 27957480 DOI: 10.1155/2016/5203898] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
98 Burke KE, Khalili H, Garber JJ, Haritunians T, McGovern DPB, Xavier RJ, Ananthakrishnan AN. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1840-8. [PMID: 29718226 DOI: 10.1093/ibd/izy083] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
99 Regmi S, Pathak S, Nepal MR, Shrestha P, Park J, Kim JO, Yong CS, Choi D, Chang J, Jeong TC, Orive G, Yook S, Jeong J. Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation. Journal of Controlled Release 2019;316:138-49. [DOI: 10.1016/j.jconrel.2019.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
100 Manguso F, Bennato R, Lombardi G, Riccio E, Costantino G, Fries W. Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166455. [PMID: 27846307 DOI: 10.1371/journal.pone.0166455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
101 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
102 Dorreen A, Heisler C, Jones J. Treatment of Inflammatory Bowel Disease in the Older Patient. Inflammatory Bowel Diseases 2018;24:1155-66. [DOI: 10.1093/ibd/izy023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
103 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
104 Li D, Yang Y, Yin X, Liu Y, Xu H, Ni Y, Hang P, Niu S, Zhang H, Ding W, Kuang H. Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa. Bioengineered 2021;12:5195-209. [PMID: 34402720 DOI: 10.1080/21655979.2021.1958600] [Reference Citation Analysis]
105 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
106 Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-sánchez JN. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology 2019;17:1788-1798.e2. [DOI: 10.1016/j.cgh.2018.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
107 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
108 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
109 Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;:CD000478. [PMID: 27192092 DOI: 10.1002/14651858.CD000478.pub4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
110 Chandrakumar A, Loeppky R, Deneau M, El-Matary W. Inflammatory Bowel Disease in Children with Elevated Serum Gamma Glutamyltransferase Levels. J Pediatr 2019;215:144-151.e3. [PMID: 31500861 DOI: 10.1016/j.jpeds.2019.07.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
111 Leddin D, Lieberman DA, Tse F, Barkun AN, Abou-setta AM, Marshall JK, Samadder NJ, Singh H, Telford JJ, Tinmouth J, Wilkinson AN, Leontiadis GI. Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus. Gastroenterology 2018;155:1325-1347.e3. [DOI: 10.1053/j.gastro.2018.08.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
112 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
113 Enns RA, Hookey L, Armstrong D, Bernstein CN, Heitman SJ, Teshima C, Leontiadis GI, Tse F, Sadowski D. Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. Gastroenterology. 2017;152:497-514. [PMID: 28063287 DOI: 10.1053/j.gastro.2016.12.032] [Cited by in Crossref: 168] [Cited by in F6Publishing: 132] [Article Influence: 33.6] [Reference Citation Analysis]
114 Cui DJ, Yang XL, Okuda S, Ling YW, Zhang ZX, Liu Q, Yuan WQ, Yan F. Gallincin ameliorates colitis-associated inflammation and barrier function in mice based on network pharmacology prediction. J Int Med Res 2020;48:300060520951023. [PMID: 33322986 DOI: 10.1177/0300060520951023] [Reference Citation Analysis]
115 Niu X, Zhang H, Li W, Wang Y, Mu Q, Wang X, He Z, Yao H. Protective effect of cavidine on acetic acid-induced murine colitis via regulating antioxidant, cytokine profile and NF-κB signal transduction pathways. Chem Biol Interact. 2015;239:34-45. [PMID: 26102009 DOI: 10.1016/j.cbi.2015.06.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
116 Sadowski DC, Camilleri M, Chey WD, Leontiadis GI, Marshall JK, Shaffer EA, Tse F, Walters JRF. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. J Can Assoc Gastroenterol 2020;3:e10-27. [PMID: 32010878 DOI: 10.1093/jcag/gwz038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
117 Zamora-pineda J, Kalinina O, Osborne BA, Knight KL. Probiotic Molecules That Inhibit Inflammatory Diseases. Applied Sciences 2022;12:1147. [DOI: 10.3390/app12031147] [Reference Citation Analysis]
118 Yan B, Feagan B, Teriaky A, Mosli M, Mohamed R, Williams G, Yeung E, Yong E, Haig A, Sey M, Stitt L, Zou GY, Jairath V. Reliability of EUS indices to detect inflammation in ulcerative colitis. Gastrointest Endosc 2017;86:1079-87. [PMID: 28760533 DOI: 10.1016/j.gie.2017.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Dan A, Boutros M, Nedjar H, Kopylov U, Afif W, Khalil MA, Rahme E. Cost of Ulcerative Colitis in Quebec, Canada: A Retrospective Cohort Study. Inflamm Bowel Dis 2017;23:1262-71. [PMID: 28691933 DOI: 10.1097/MIB.0000000000001147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
120 Meijer B, Mulder CJJ, Bouma G, Ponsioen CY, van der Woude CJ, van der Meulen AE, Wintjens DSJ, Dijkstra G, Hoentjen F, Oldenburg B, van Bodegraven AA, de Boer NKH; Dutch Initiative on Crohn and Colitis (ICC) and Parelsnoer Institute. Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflammatory Bowel Diseases 2018;24:1558-65. [DOI: 10.1093/ibd/izy047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Liu LWC, Andrews CN, Armstrong D, Diamant N, Jaffer N, Lazarescu A, Li M, Martino R, Paterson W, Leontiadis GI, Tse F. Clinical Practice Guidelines for the Assessment of Uninvestigated Esophageal Dysphagia. J Can Assoc Gastroenterol 2018;1:5-19. [PMID: 31294391 DOI: 10.1093/jcag/gwx008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
122 Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
123 Zhang Z, Liu J, Shen P, Cao Y, Lu X, Gao X, Fu Y, Liu B, Zhang N. Zanthoxylum bungeanum pericarp extract prevents dextran sulfate sodium-induced experimental colitis in mice via the regulation of TLR4 and TLR4-related signaling pathways. International Immunopharmacology 2016;41:127-35. [DOI: 10.1016/j.intimp.2016.10.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
124 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019;68:977-984. [PMID: 30420398 DOI: 10.1136/gutjnl-2018-317021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
126 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
127 Danese S, Neurath MF, Kopoń A, Zakko SF, Simmons TC, Fogel R, Siegel CA, Panaccione R, Zhan X, Usiskin K, Chitkara D. Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:2526-2534.e9. [PMID: 31926340 DOI: 10.1016/j.cgh.2019.12.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
128 Shahidi N, Bressler B, Panaccione R. Vedolizumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 2015;16:129-35. [DOI: 10.1517/14712598.2016.1121231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
130 Dai YC, Zheng L, Zhang YL, Chen X, Chen DL, Wang LJ, Tang ZP. Jianpi Qingchang decoction regulates intestinal motility of dextran sulfate sodium-induced colitis through reducing autophagy of interstitial cells of Cajal. World J Gastroenterol 2017; 23(26): 4724-4734 [PMID: 28765693 DOI: 10.3748/wjg.v23.i26.4724] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
131 Rodrigues R, Guerra G, Soares J, Santos K, Rolim F, Assis P, Araújo D, de Araújo Júnior RF, Garcia VB, de Araújo AA, Queiroga R. Lactobacillus rhamnosus EM1107 in goat milk matrix modulates intestinal inflammation involving NF-κB p65 and SOCs-1 in an acid-induced colitis model. Journal of Functional Foods 2018;50:78-92. [DOI: 10.1016/j.jff.2018.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
132 Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S653-68. [PMID: 29767705 DOI: 10.1093/ecco-jcc/jjy060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
133 Wu M, Shen A, Chen Y, Liu L, Li L, Sankararaman S, Chen H, Guan B, Zhan Z, Nan S, Sferra TJ, Peng J. Xinhuang Tablets Improve Intestinal Barrier Function via Regulating Epithelial Tight Junctions in Dextran Sulfate Sodium-Induced Ulcerative Colitis Mice. J Med Food 2021;24:33-9. [PMID: 32522051 DOI: 10.1089/jmf.2020.0008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Ananthakrishnan AN, Kane SV. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. Gastroenterology 2015;148:877-80. [PMID: 25805424 DOI: 10.1053/j.gastro.2015.03.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Lin SC, Cheifetz AS. The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2018;14:415-425. [PMID: 30166957 DOI: 10.1007/978-94-011-4002-7_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
138 Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of vedolizumab for the treatment of ulcerative colitis.Expert Opin Drug Saf. 2017;16:501-507. [PMID: 28276855 DOI: 10.1080/14740338.2017.1300251] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
139 Araújo DFS, Guerra GCB, Pintado MME, Sousa YRF, Algieri F, Rodriguez-Nogales A, Araújo RF Jr, Gálvez J, Queiroga RCRE, Rodriguez-Cabezas ME. Intestinal anti-inflammatory effects of goat whey on DNBS-induced colitis in mice. PLoS One 2017;12:e0185382. [PMID: 28957373 DOI: 10.1371/journal.pone.0185382] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
140 Liu X, Fan Y, Du L, Mei Z, Fu Y. In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis. Front Pharmacol 2021;12:665102. [PMID: 34177580 DOI: 10.3389/fphar.2021.665102] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112:775-784. [PMID: 28323273 DOI: 10.1038/ajg.2017.46] [Cited by in Crossref: 281] [Cited by in F6Publishing: 210] [Article Influence: 56.2] [Reference Citation Analysis]
142 Chiarella-Redfern H, Lee S, Jubran B, Sharifi N, Panaccione R, Constantinescu C, Benchimol EI, Seow CH. Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. Inflamm Bowel Dis 2021:izab033. [PMID: 33609034 DOI: 10.1093/ibd/izab033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
144 Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2019;2:6-29. [PMID: 31294724 DOI: 10.1093/jcag/gwy071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
145 Xiao M, Shen Z, Luo W, Tan B, Meng X, Wu X, Wu S, Nie K, Tong T, Hong J, Wang X, Wang X. A new colitis therapy strategy via the target colonization of magnetic nanoparticle-internalized Roseburia intestinalis. Biomater Sci 2019;7:4174-85. [PMID: 31380882 DOI: 10.1039/c9bm00980a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
146 Chen YL, Zhang YL, Dai YC, Tang ZP. Systems pharmacology approach reveals the antiinflammatory effects of Ampelopsis grossedentata on dextran sodium sulfate-induced colitis. World J Gastroenterol 2018; 24(13): 1398-1409 [PMID: 29632421 DOI: 10.3748/wjg.v24.i13.1398] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
147 Davis SC, Robinson BL, Vess J, Lebel JS. Primary care management of ulcerative colitis. The Nurse Practitioner 2018;43:11-9. [DOI: 10.1097/01.npr.0000527565.05934.14] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
148 Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflamm Bowel Dis 2020;26:941-8. [PMID: 31560046 DOI: 10.1093/ibd/izz204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
149 Ilias A, Gonczi L, Kurti Z, Lakatos PL. Biosimilars in ulcerative colitis: When and for who? Best Practice & Research Clinical Gastroenterology 2018;32-33:35-42. [DOI: 10.1016/j.bpg.2018.05.003] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Jean L, Audrey M, Beauchemin C, Consortium OBOTI. Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Can J Gastroenterol Hepatol 2018;2018:7439730. [PMID: 30009158 DOI: 10.1155/2018/7439730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
151 Zhang H, Song G, Zhang Z, Song H, Tang X, Deng A, Wang W, Wu L, Qin H. Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway. Front Pharmacol 2017;8:619. [PMID: 28928666 DOI: 10.3389/fphar.2017.00619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
152 Cardile S, Alterio T, Candusso M, Pietrobattista A, Liccardo D, Basso MS, Papadatou B, Bracci F, Knafelz D, Torre G. Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives. Scand J Gastroenterol 2017;52:662-7. [PMID: 28281846 DOI: 10.1080/00365521.2017.1298833] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:116-125.e5. [PMID: 33039585 DOI: 10.1016/j.cgh.2020.10.004] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
154 Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2017;29:322-330. [PMID: 27879485 DOI: 10.1097/meg.0000000000000783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
155 Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018;155:1098-1108.e9. [PMID: 29964043 DOI: 10.1053/j.gastro.2018.06.046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
156 Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
157 Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 31.5] [Reference Citation Analysis]
158 Zhong C, Cheng X, Jia B, Xiong P, Lu J, Zhang P, Liu X, Chen Y. Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23038. [PMID: 33217804 DOI: 10.1097/MD.0000000000023038] [Reference Citation Analysis]
159 Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology 2019;17:1680-713. [DOI: 10.1016/j.cgh.2019.02.043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
160 Sun YX, Yang GY, Karamacoska D, Wang X, Li YX, Hou WB, Zheng YY, Liu JP, Liu ZL. Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2021;2021:1075886. [PMID: 34484384 DOI: 10.1155/2021/1075886] [Reference Citation Analysis]
161 Stern S, Ward AJ, Saint-laurent Thibault C, Camacho F, Rahme E, Naessens D, Aumais G, Bernard E, Bourdages R, Cohen A, Pare P, Dyrda P. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of Medical Economics 2018;21:27-37. [DOI: 10.1080/13696998.2017.1371033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
162 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
163 Yarlas A, D'Haens G, Willian MK, Teynor M. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflamm Bowel Dis. 2018;24:450-463. [PMID: 29361097 DOI: 10.1093/ibd/izx041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
164 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
165 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
166 Zheng K, Shen H, Jia J, Lu Y, Zhu L, Zhang L, Shen Z. Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. Trials. 2017;18:8. [PMID: 28069051 DOI: 10.1186/s13063-016-1763-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
167 Zhang Z, Shen P, Xie W, Cao H, Liu J, Cao Y, Zhang N. Pingwei San ameliorates dextran sulfate sodium-induced chronic colitis in mice. J Ethnopharmacol 2019;236:91-9. [PMID: 30844487 DOI: 10.1016/j.jep.2019.01.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
168 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Reference Citation Analysis]
169 Zheng L, Zhang YL, Dai YC, Chen X, Chen DL, Dai YT, Tang ZP. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation. World J Gastroenterol 2017; 23(7): 1180-1188 [PMID: 28275298 DOI: 10.3748/wjg.v23.i7.1180] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
170 Zhang Z, Li Y, Shen P, Li S, Lu X, Liu J, Cao Y, Liu B, Fu Y, Zhang N. Administration of geniposide ameliorates dextran sulfate sodium-induced colitis in mice via inhibition of inflammation and mucosal damage. Int Immunopharmacol 2017;49:168-77. [PMID: 28595080 DOI: 10.1016/j.intimp.2017.05.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
171 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
172 Deng Z, Liu Q, Wang M, Wei HK, Peng J. GPA Peptide-Induced Nur77 Localization at Mitochondria Inhibits Inflammation and Oxidative Stress through Activating Autophagy in the Intestine. Oxid Med Cell Longev 2020;2020:4964202. [PMID: 32904539 DOI: 10.1155/2020/4964202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
173 Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:858-65. [PMID: 28509817 DOI: 10.1097/MIB.0000000000001152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
174 Wilson A, Wang Q, Choi YH, Ponich T, Gregor JC, Chande N, Yan B, Sey M, Beaton M, Kim RB. Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clin Transl Gastroenterol 2021;12:e00332. [PMID: 33821842 DOI: 10.14309/ctg.0000000000000332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Cao Y, Zhang B, Wu Y, Wang Q, Wang J, Shen F. The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5480961. [PMID: 29849592 DOI: 10.1155/2018/5480961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
176 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Zhang Z, Shen P, Lu X, Li Y, Liu J, Liu B, Fu Y, Cao Y, Zhang N. In Vivo and In Vitro Study on the Efficacy of Terpinen-4-ol in Dextran Sulfate Sodium-Induced Mice Experimental Colitis. Front Immunol. 2017;8:558. [PMID: 28553294 DOI: 10.3389/fimmu.2017.00558] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
178 Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: A meta-analysis. Inflamm Bowel Dis. 2016;22:1859-1869. [PMID: 27206015 DOI: 10.1097/mib.0000000000000816] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 15.3] [Reference Citation Analysis]
179 Stallmach A, Schmidt C, Teich N. Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2015;10:165-75. [DOI: 10.1586/17474124.2016.1123618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
180 Limdi JK, Farraye J, Cannon R, Woodhams E, Farraye FA. Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know. Inflamm Bowel Dis. 2019;25:1603-1612. [PMID: 30877770 DOI: 10.1093/ibd/izz025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
181 Carman N, Mack DR, Benchimol EI. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0623-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
182 Cargnin S, Genazzani AA, Canonico PL, Terrazzino S. Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis. Pharmacological Research 2018;135:102-11. [DOI: 10.1016/j.phrs.2018.07.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
183 Cheng H, Ma Z, Yu B, Liu X, Tian C, Zhong X, Zhao L. Quality assessment of clinical guidelines on probiotics therapy in children with IBD using the AGREE II instrument. J Clin Pharm Ther 2021;46:1155-65. [PMID: 33768598 DOI: 10.1111/jcpt.13422] [Reference Citation Analysis]
184 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
185 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Reference Citation Analysis]
186 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
187 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Reference Citation Analysis]
188 Yuan J, Cheng W, Zhang G, Ma Q, Li X, Zhang B, Hu T, Song G. Protective effects of iridoid glycosides on acute colitis via inhibition of the inflammatory response mediated by the STAT3/NF-кB pathway. Int Immunopharmacol 2020;81:106240. [PMID: 32044657 DOI: 10.1016/j.intimp.2020.106240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
189 Sadowski DC, Camilleri M, Chey WD, Leontiadis GI, Marshall JK, Shaffer EA, Tse F, Walters JRF. Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clin Gastroenterol Hepatol 2020;18:24-41.e1. [PMID: 31526844 DOI: 10.1016/j.cgh.2019.08.062] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
190 Balram B, Joshi H, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Baumgart DC, Peerani F. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Dig Dis Sci 2021;66:3985-92. [PMID: 33184796 DOI: 10.1007/s10620-020-06704-6] [Reference Citation Analysis]
191 Ou G, Bressler B, Galorport C, Lam E, Ko HH, Enns R, Telford J, Schaffer N, Lee T, Rosenfeld G. Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study. J Can Assoc Gastroenterol 2018;1:99-106. [PMID: 31294728 DOI: 10.1093/jcag/gwy023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
192 Cheng Y, Cheng C, Yao J, Yu Y, Liu Y, Zhang H, Miao L, Wei H. Mn 3 O 4 Nanozyme for Inflammatory Bowel Disease Therapy. Adv Therap 2021;4:2100081. [DOI: 10.1002/adtp.202100081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Allamneni C, Venkata K, Yun H, Xie F, DeLoach L, Malik TA. Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center. Gastroenterology Res 2018;11:41-5. [PMID: 29511405 DOI: 10.14740/gr934w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
194 Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res 2018;16:522-8. [PMID: 30321913 DOI: 10.5217/ir.2018.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
195 Jin QW, Wang XD. Progress in research of vedolizumab in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 248-255 [DOI: 10.11569/wcjd.v29.i5.248] [Reference Citation Analysis]
196 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
197 Palumbo VD, Romeo M, Gammazza AM, Carini F, Damiani P, Damiano G, Buscemi S, Lo Monte AI, Gerges-geagea A, Jurjus A, Tomasello G. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:372-7. [DOI: 10.5507/bp.2016.044] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
198 Castaneda G, Liu B, Torres S, Bhuket T, Wong RJ. Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study. Dig Dis Sci 2017;62:2876-81. [PMID: 28856475 DOI: 10.1007/s10620-017-4733-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
199 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
200 Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. J Med Econ. 2019;22:859-868. [PMID: 31012362 DOI: 10.1080/13696998.2019.1609481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]